


Celerion Leadership in Early Clinical Oncology Development

At Celerion, we understand the importance of timing, experience and flexibility for the successful execution of an oncology study. Celerion has successfully supported oncology studies covering over 25 indications within this complex therapeutic area.

Our experience across disease states, countries and therapeutic modalities will add value to your study by providing access to key investigators, experienced study centers, networks of specialized labs (CTC/DTC/PBMC), insightful study design and highly skilled project teams.

Celerion has designed and conducted programs in the rapidly expanding area of clinical immuno-oncology in indications such as prostate cancer, ovarian cancer and colorectal carcinoma, to name a few.



810 Sites



26 Countries



5800 Subjects



WHY CELERION

The clinical research professionals at Celerion have extensive experience and expertise in managing complex patient studies, helping you to transition through Proof-of-Concept and beyond.

Celerion's team works within a robust quality management system to ensure high-quality results demanded of a highly regulated industry

- Save valuable time and budget with experienced project managers and streamlined processes.
- Gain critical insight from protocol development to study conduct through Celerion's accumulated experience of nearly 1000 studies in over 30 countries.
- Minimize risk through early problem identification, implementation of mitigation strategies, and through close monitoring of project plans and key project and decision drivers.
- Facilitate execution through well-trained and organized teams with rapid access to senior management and streamlined communication.
- Assure compliance and data integrity through monitoring plans tailored to each specific study, whether using our CORE Monitoring approach, deploying risk-based monitoring, or a custom solution.

